SRES-752-119
Referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S2447)
Sponsored by Richard Blumenthal (D-CT)
What it does
This resolution would express the Senate's support for designating May 2026 as "Progressive Supranuclear Palsy and Corticobasal Degeneration Awareness Month." It would also formally support research into diagnosis, prevention, treatments, and cures for both diseases, and commend patients, caregivers, healthcare professionals, and researchers working in this area. The resolution carries no legal force, creates no new programs, and appropriates no funds.
Who benefits
The approximately 30,000 Americans living with progressive supranuclear palsy (PSP) and roughly 2,000 living with corticobasal degeneration (CBD), who may gain increased public visibility for their conditions. Family caregivers and loved ones of patients, who may benefit from greater awareness and reduced social isolation. Neurologists and researchers specializing in these diseases, who may see increased public and institutional interest in their work. Patient advocacy organizations focused on rare neurodegenerative diseases, which may gain a platform for outreach.
Who is hurt
No group faces a direct material harm from this resolution. There are no mandates, spending changes, or regulatory burdens created. Competing rare disease advocacy groups may experience marginally reduced attention during the designated month, though this effect would be negligible.
Supporters argue
Supporters argue that PSP and CBD are severely underdiagnosed — frequently mistaken for Parkinson's disease or frontotemporal dementia — and that the roughly 32,000 Americans affected face a median survival of only 7 to 8 years from symptom onset with no disease-modifying treatments available. They contend that a formal Senate designation raises public and medical community awareness, potentially accelerating earlier diagnosis and encouraging research funding for conditions that currently lack any cure or effective treatment.
Opponents argue
Opponents might argue that commemorative resolutions consume limited legislative floor time and committee resources without creating any enforceable commitment to research funding or patient support services. They could contend that the Senate's expression of "support" for research carries no appropriations authority and that, without accompanying legislation directing NIH funding or insurance coverage changes, the resolution may offer symbolic comfort to affected communities while leaving the underlying gaps in diagnosis, treatment, and caregiver support unaddressed.
Constitutional context
No significant constitutional issues are raised by this resolution. It is a purely expressive, non-binding Senate resolution that does not invoke the Commerce Clause, Taxing and Spending Clause, or any other enumerated power in a legally operative way.
Checks and balances
The Senate expresses a non-binding opinion; no executive branch agency gains or loses authority, and no judicial review is implicated because the resolution creates no enforceable legal rights or obligations.
Historical precedent
Congress regularly passes similar commemorative resolutions designating awareness months for rare diseases, such as prior resolutions recognizing ALS Awareness Month and Rare Disease Day, though none are directly analogous in subject matter.